表紙:喘息-2029年までの世界の医薬品予測と市場分析
市場調査レポート
商品コード
979397

喘息-2029年までの世界の医薬品予測と市場分析

Asthma - Global Drug Forecast and Market Analysis to 2029

出版日: | 発行: GlobalData | ページ情報: 英文 123 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=110.22円
喘息-2029年までの世界の医薬品予測と市場分析
出版日: 2020年12月31日
発行: GlobalData
ページ情報: 英文 123 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

喘息は一般的な慢性肺疾患であり、小児期に発症することが最も多く、またどの年齢でも発症する可能性があります。慢性的な炎症とそれに続く気道の狭窄を特徴とし、肺を通る空気の通過を妨げます。喘息は持続性または断続性となる場合があり、重症度も様々です。喘息の治療には段階的なアプローチがあり、病気の重症度が増すにつれて治療のレベルが上がります。喘息が非常に不均一な疾患であるため、これらの標的療法にも様々な種類があり、そのうちのいくつかは現在後期段階のパイプラインにあります。トリプル吸入療法は、中等度から重度の喘息患者への適合率を高めるために、予測期間にわたって患者シェアが増加すると予測されています。

当レポートは、市販および後期パイプラインの喘息治療薬の市場予測を網羅しています。また喘息患者を重症度別に分類します。2019年を基準年とし、2020年から2029年の予測をまとめています。

目次

第1章 目次

  • 表リスト
  • 図リスト

第2章 喘息:エグゼクティブサマリー

  • 喘息市場は予測期間にわたって保守的な成長となる
  • GlaxoSmithKlineとAstraZenecaが先導する
  • 重度の喘息患者のための診断と治療の選択肢を取り巻くアンメットニーズ
  • 後期パイプラインは、個別化された利便性の高い医薬品のニーズに対応
  • 医師の見解

第3章 イントロダクション

  • 促進因子
  • 関連レポート
  • 今後の関連レポート

第4章 病気の概要

  • 病因と病態生理学
    • 病因
    • 病態生理学
  • 疾病の重症度の分類

第5章 疫学

  • 病気の背景
  • 危険因子と併存疾患
  • 世界的動向および歴史的動向
  • 予測調査手法
    • ソース
    • 予測の前提条件と方法
  • 喘息の疫学予測(2019-2029)
    • 喘息の生涯診断有病率
    • 喘息の年齢別生涯診断有病率
    • 喘息の性別生涯診断有病率
    • 喘息の重症度別生涯診断有病率
  • 議論
    • 疫学予測の洞察
    • 分析の限界
    • 分析の強み

第6章 疾病管理

  • 診断と治療の概要
    • 診断
    • 治療ガイドラインと臨床診療
  • 米国
  • EU5か国
  • 日本

第7章 競争力評価

  • 概要

第8章 ニーズと機会の評価

  • 概要
  • 正確な診断
  • 重度の喘息のための個別化された治療法
  • 患者適合性向上
  • 治療費の削減

第9章 パイプライン評価

  • 概要
  • 臨床開発における有望な医薬品
    • 胸腺間質リンホポイエチン阻害剤
    • CRTH2拮抗薬
    • 吸入コルチコステロイド/長時間作用型ベータ作動薬/長時間作用型ムスカリン拮抗薬
  • その他の開発中の薬

第10章 現在および将来のプレーヤー

  • 概要
  • 企業戦略の動向
  • AstraZeneca
  • Novartis
  • Roche/Genentech
  • GlaxoSmithKline
  • Teva
  • Boehringer Ingelheim
  • Merck
  • Chiesi
  • Regeneron/Sanofi
  • AB Science SA

第11章 市場の見通し

  • 世界市場
    • 予測
    • 推進要因と障壁-世界の問題
  • 米国
    • 予測
    • 重要イベント
    • 成長要因と障壁
  • EU5か国
    • 予測
    • 重要イベント
    • 成長要因と障壁
  • 日本
    • 予測
    • 重要イベント
    • 成長要因と障壁

第12章 付録

図表

List of Tables

List of Tables

  • Table 1: Asthma: Key Metrics in the 7MM
  • Table 2: Classification of Asthma by Severity
  • Table 3: Risk Factors and Comorbidities for Asthma
  • Table 4: Treatment Guidelines for Asthma across the 7MM
  • Table 5: Dosing of Common ICSs for Adult Asthma Therapy to Achieve Equivalent Therapeutic Potency
  • Table 6: Country Profile - US
  • Table 7: Country Profile - 5EU
  • Table 8: Country Profile - Japan
  • Table 9: Leading Treatments for Asthma, 2020
  • Table 10: AstraZeneca's Asthma Portfolio Assessment, 2020
  • Table 11: Novartis' Asthma Portfolio Assessment, 2020
  • Table 12: Roche/Genentech Asthma Portfolio Assessment, 2020
  • Table 13: GlaxoSmithKline's Asthma Portfolio Assessment, 2020
  • Table 14: Teva's Asthma Portfolio Assessment, 2020
  • Table 15: Boehringer Ingelheim's Asthma Portfolio Assessment, 2020
  • Table 16: Merck's Asthma Portfolio Assessment, 2020
  • Table 17: Chiesi's COPD Portfolio Assessment, 2019
  • Table 18: Regeneron/Sanofi's Asthma Portfolio Assessment, 2020
  • Table 19: AB Science Asthma Portfolio Assessment, 2020
  • Table 20: Asthma Market - Global Drivers and Barriers, 2019-2029
  • Table 21: Key Events Impacting Sales for Asthma in the US, 2019-2029
  • Table 22: Asthma Market - Drivers and Barriers in the US, 2019-2029
  • Table 23: Key Events Impacting Sales for Asthma in the 5EU, 2019-2029
  • Table 24: Asthma Market - Drivers and Barriers in the 5EU, 2019-2029
  • Table 25: Key Events Impacting Sales for Asthma in Japan, 2019-2029
  • Table 26: Asthma Market - Global Drivers and Barriers in Japan, 2019-2029
  • Table 27: Key Historical and Projected Launch Dates for Asthma
  • Table 28: Key Historical and Projected Patent Expiry Dates for Asthma
  • Table 29: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

List of Figures

  • Figure 1: Global Sales Forecast by Country for Asthma in 2019 and 2029
  • Figure 2: Analysis of the Company Portfolio Gap in Asthma During the Forecast Period
  • Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents for Asthma, 2020
目次
Product Code: GDHC208PIDR

Asthma - Global Drug Forecast and Market Analysis to 2029

Asthma is a common chronic lung disease that most often develops during childhood, although it can occur at any age. It is characterized by chronic inflammation and subsequent narrowing of the airways, which obstructs the passage of air through the lungs. Asthma can be persistent or intermittent, and also varies in severity. The treatment of asthma involves a step-wise approach, where the level of therapy increases as the disease severity increases. The realization that asthma is a very heterogeneous disease is highly reflected in the rich assortment of these targeted therapies, of which some are currently in the late-stage pipeline. Triple inhaled therapies are forecasted to grow in patient share over the forecasted period to increase compliance rates amongst moderate to severe asthma patients.

This model covers the market forecast for the marketed and late-stage pipeline asthma therapeutics. The model segments asthma patients by severity. The base year of this model is 2019, and the forecast period is 2020-2029.

Key Highlights

  • The greatest drivers of growth in the global asthma market include the launch of six new pipeline therapies during the forecast period and an increasing diagnosed prevalence in many 7MM countries.
  • The main barriers to growth in the asthma market include high genericization of historical drug classes.
  • Late-stage pipeline products in the ICS/LABA/LAMA triple-therapy fixed dose inhalers, CRTH2 antagonists, and ICS/SABA double therapies are emerging as distinct drug classes in the field.
  • The most important unmet needs in the asthma market are improved drug compliance and personalized therapy for the most severe patients.

KEY QUESTIONS ANSWERED

  • Which unmet needs are limiting the treatment of asthma in the 7MM?
  • What strategies can the pharmaceutical industry employ to increase treatment rates for asthma? How should these strategies differ across different geographical markets?
  • What effect will the launch of generics have on the sales of branded agents?
  • What are the main R&D trends in the asthma market and which companies are leading the way? Are there major differences in the mechanisms of action used by therapies in late-stage versus early-stage clinical development?

Scope

  • Overview of asthma including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Topline asthma market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.
  • Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting asthma therapeutics sales in the 7MM.
  • Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the global asthma therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
  • Develop business strategies by understanding the trends shaping and driving the global asthma therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global asthma market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global asthma therapeutics market from 2019-2029.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1 Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Asthma: Executive Summary

  • 2.1 Asthma Market to Experience Conservative Growth Over the Forecast Period
  • 2.2 GlaxoSmithKline and AstraZeneca Lead the Way
  • 2.3 Unmet Needs Remain Surrounding Asthma Diagnosis and Treatment Options for Severe Patients
  • 2.4 Late-Stage Pipeline Addresses Needs for Personalized and Convenient Medications
  • 2.5 What Do Physicians Think?

3 Introduction

  • 3.1 Catalyst
  • 3.2 Related Reports
  • 3.3 Upcoming Related Reports

4 Disease Overview

  • 4.1 Etiology and Pathophysiology
    • 4.1.1 Etiology
    • 4.1.2 Pathophysiology
  • 4.2 Classification of Disease Severity

5 Epidemiology

  • 5.1 Disease Background
  • 5.2 Risk Factors and Comorbidities
  • 5.3 Global and Historical Trends
  • 5.4 Forecast Methodology
    • 5.4.1 Sources
    • 5.4.2 Forecast Assumptions and Methods
  • 5.5 Epidemiological Forecast for Asthma (2019-2029)
    • 5.5.1 Lifetime Diagnosed Prevalent Cases of Asthma
    • 5.5.2 Age-Specific Lifetime Diagnosed Prevalent Cases of Asthma
    • 5.5.3 Sex-Specific Lifetime Diagnosed Prevalent Cases of Asthma
    • 5.5.4 Lifetime Diagnosed Prevalent Cases of Asthma by Severity
  • 5.6 Discussion
    • 5.6.1 Epidemiological Forecast Insight
    • 5.6.2 Limitations of Analysis
    • 5.6.3 Strengths of Analysis

6 Disease Management

  • 6.1 Diagnosis and Treatment Overview
    • 6.1.1 Diagnosis
    • 6.1.2 Treatment Guidelines and Clinical Practice
  • 6.2 US
  • 6.3 5EU
  • 6.4 Japan

7 Competitive Assessment

  • 7.1 Overview

8 Needs and Opportunity Assessment

  • 8.1 Overview
  • 8.2 Accurate Diagnosis
  • 8.3 Personalized Therapies for Severe Asthma
  • 8.4 Increased Patient Compliance
  • 8.5 Lower Cost of Therapy

9 Pipeline Assessment

  • 9.1 Overview
  • 9.2 Promising Drugs in Clinical Development
    • 9.2.1 Thymic Stromal Lymphopoietin Inhibitors
    • 9.2.2 CRTH2 Antagonist
    • 9.2.3 Inhaled Corticosteroid/Long-Acting Beta-Agonist/Long-Acting Muscarinic Antagonist
  • 9.3 Other Drugs in Development

10 Current and Future Players

  • 10.1 Overview
  • 10.2 Trends in Corporate Strategy
  • 10.3 AstraZeneca
  • 10.4 Novartis
  • 10.5 Roche/Genentech
  • 10.6 GlaxoSmithKline
  • 10.7 Teva
  • 10.8 Boehringer Ingelheim
  • 10.9 Merck
  • 10.10 Chiesi
  • 10.11 Regeneron/Sanofi
  • 10.12 AB Science SA

11 Market Outlook

  • 11.1 Global Markets
    • 11.1.1 Forecast
    • 11.1.2 Drivers and Barriers - Global Issues
  • 11.2 US
    • 11.2.1 Forecast
    • 11.2.2 Key Events
    • 11.2.3 Drivers and Barriers
  • 11.3 5EU
    • 11.3.1 Forecast
    • 11.3.2 Key Events
    • 11.3.3 Drivers and Barriers
  • 11.4 Japan
    • 11.4.1 Forecast
    • 11.4.2 Key Events
    • 11.4.3 Drivers and Barriers

12 Appendix